Everest Organics Limited, an API manufacturer, reported a profit of Rs 140.52 lakhs for Q1 FY2026, reversing a loss of Rs 608.96 lakhs from the previous year. Revenue from operations increased to Rs 5,381.32 lakhs. The board approved reappointments of Dr. Srikakarlapudi Sirisha as Managing Director and Mr. Srikakarlapudi Harikrishna as Whole-time Director, both for three-year terms. Ms. Shweta Singh was appointed as the new Company Secretary. The company's 32nd AGM is scheduled for September 27, 2025. Auditors raised concerns about enhanced production levels without necessary approvals from TSPCB, potentially affecting the company's going concern status. Management is addressing this issue and has applied for required approvals.
18Feb 25
Everest Organics Secures Korean Drug Master File Approval for Rabeprazole Sodium API
Everest Organics Limited has obtained Drug Master File (DMF) approval from Korean authorities for its Rabeprazole Sodium API on February 18, 2025. This approval allows the company to export the API, used in treating excessive stomach acid conditions, to the South Korean market. The development marks a significant milestone in Everest Organics' international expansion efforts and opens up new revenue opportunities in the Korean pharmaceutical industry.